Quick Takeaways Why It Matters? Gallant is on track to create one of the first mass‑market, disease‑modifying OA biologics in companion animals, shifting regenerative medicine from niche referral centers into everyday general practice via a simple, ready‑to‑use IV product. ...
Quick Takeaways: Why It Matters? Gallant’s positive UMSC pilot data and FDA CVM’s expanded conditional approval eligibility together position this program as a potential first‑in‑class, disease‑modifying biologic in an almost empty feline OA toolbox. By showing up to...
Quick Takeaways: Why It Matters? The partnership gives Gallant industrial‑grade cold-chain logistics, solving a key bottleneck for scaling allogeneic cell therapies beyond a few specialty centers. For MWI/Cencora, establishing -80°C capability positions the ...
